Reditux - Rituximab 100 mg Inj

Rituximab is a monoclonal antibody that works by specifically targeting a protein called CD20, found on the surface of certain white blood cells known as B-lymphocytes. By binding to this protein, Rituximab helps the immune system identify and eliminate these targeted cells, which can be beneficial in conditions where abnormal or overactive B-cells contribute to disease. It is commonly used in the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, where it helps reduce the population of cancerous B-cells. Rituximab is also used to manage certain autoimmune conditions, such as rheumatoid arthritis, particularly in patients who have not responded adequately to other treatments. The medication is administered through intravenous infusion, typically in a hospital or specialized clinical setting, allowing healthcare providers to closely monitor the patient during administration. Treatment schedules and dosing are carefully tailored based on the specific condition being treated and the patient's individual health profile. Premedication is often given before infusion to help minimize infusion-related reactions and improve patient comfort. Many patients experience meaningful disease control and symptom improvement with Rituximab as part of their treatment plan. As with all specialized therapies, it should be administered under the close supervision of experienced healthcare professionals as part of a comprehensive treatment strategy.